Abstracts tagged "Antimalarial drugs"

Abstract Number: 2526 • 2019 ACR/ARP Annual Meeting
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus
Ioannis Parodis¹, Sofia Soukka ¹, Alvaro Gomez ¹, Yvonne Enman ¹, Petter Johansson ¹, Sharzad Emamikia ¹ and Katerina Chatzidionysiou ¹, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffer an impaired health-related quality of life (HRQoL), and the majority of them experience fatigue as a major…
Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Gemma Cramarossa¹, Janet Pope ² and Matthew Turk ³, ¹Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Western University, London, ON, Canada, ³University of Western Ontario, London, ON, Canada
Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
Abstract Number: 2897 • 2019 ACR/ARP Annual Meeting
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Majid Zeidi ¹, Kristen Chen ¹, Krisha Desai ¹, Hee Joo Kim ², Srita Chakka ³, Rachel Lim ⁴ and Victoria Werth¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA andDepartment of Dermatology, University of Pennsylvania, Philadelphia, PA, USA and Department of Dermatology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea, Republic of (South), Philadelphia, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ⁴Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia
Background/Purpose: Cutaneous lupus erythematosus (CLE) is an autoimmune disease with various subsets and clinical manifestations. T lymphocytes are the predominant cell type found in lesional…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…
Abstract Number: 496 • 2018 ACR/ARHP Annual Meeting
Heart Failure Risk Among Patients with Rheumatoid Arthritis: Association with Anti-Rheumatic Drugs
Michael Ahlers¹, C. Michael Stein², Cecilia P. Chung², Michelle J. Ormseth³, Eric Farber-Eger³ and Deepak Gupta⁴, ¹4906 illinois avenue, Vanderbilt University School of Medicine, Nashville, TN, ²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Internal Medicine - Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of coronary artery disease (CAD), but the association with heart failure (HF) is less characterized. We…
Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
Wenlu Xiong¹, J.B. Boone¹, Cecilia P. Chung¹, Leslie Crofford² and April Barnado², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…
Abstract Number: 714 • 2017 ACR/ARHP Annual Meeting
Prolonged Antimalarial Treatment Is Associated with Increased Risk for Elevated Myocardial Biomarkers in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Paula Harvey³, Shadi Akhtari³, Jiandong Su⁴ and Murray Urowitz², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Antimalarial (AM)-induced cardiomyopathy (AMIC) has been rarely reported in systemic lupus erythematosus (SLE). However, given the large number of patients treated, it seems possible…
Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Gaurav Sharma¹, Jasvinder A. Singh², Mohammed Sohaib Khaleel³ and Shristi Shrestha⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, UAB School of Medicine, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Department of Molecular Cardiology, University of Louisville, Louisville, KY, ⁴Internal Medicine, Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…
Abstract Number: 2613 • 2017 ACR/ARHP Annual Meeting
Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Lavanya Mittal¹, Lingqiao Zhang², Rui Feng² and Victoria Werth¹, ¹Department of Dermatology, Corporal Michael J. Crescenz VAMC, Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although existing evidence demonstrates the efficacy of antimalarials for rheumatic skin disease, the safety of these medications, and particularly quinacrine, remain debated. Quinacrine may…
Abstract Number: 2984 • 2016 ACR/ARHP Annual Meeting
Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse
Jie An¹, Joshua Woodward², Mark Minie³, Xizhang Sun⁴, Lena Tanaka¹, Yufeng Peng¹, Jessica Snyder⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Type I interferon, (IFN-I) is strongly implicated in the pathogenesis of SLE as well as rare monogenic ‘interferonopathies’ such as Aicardi-Goutieres Syndrome (AGS) caused…
Abstract Number: 1813 • 2015 ACR/ARHP Annual Meeting
Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Jie An¹, Joshua Woodward², Mark Minie³, YuFeng Peng⁴, Tomikazu Sasaki⁵ and Keith B. Elkon⁶, ¹Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, ²Department of Microbiology, University of Washington, Seattle, WA, ³Department of Bioengineering, University of Washington, Seattle, WA, ⁴Rheumatology, University of Washington, Seattle, WA, ⁵Department of Chemistry, University of Washington, Seattle, WA, ⁶Department of Medicine & Immunology, University of Washington, Seattle, WA
Background/Purpose: Anti-malarial drugs (AMD) such as Hydroxychloroquine (HCQ) and Quinacrine (QC) are effective in the treatment of skin rash and arthritis in systemic lupus erythematosus…
Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Eugenia Enriquez Merayo¹, Maria Galindo Izquierdo², Esther Rodriguez-Almaraz³, Maria Martin Lopez², Otto Martin Olivas Vergara⁴, Patricia E. Carreira⁵ and Isabel Mateo⁶, ¹RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, ²RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ³Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ⁵Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
Abstract Number: 2832 • 2013 ACR/ARHP Annual Meeting
The Effect Of Maternal Antimalarial Intake During Pregnancy On The Risk Of Neonatal Lupus
Julie Barsalou¹, Edgar Jaeggi² and Earl D. Silverman¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Neonatal Lupus (NLE) results from passive transfer of anti-Ro and/or anti-La antibodies to the fetus during gestation. It has been suggested that prenatal exposure…
Abstract Number: 1613 • 2013 ACR/ARHP Annual Meeting
Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist
Ou Jin¹, Xi Zhang¹, Qiuxia Li¹, Lingkai Fang¹, Hongyue Huang¹, Chengcheng Hou¹, Zetao Liao¹, Qiujing Wei¹, Zhiming Lin², Dongfang Lin¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Toll-like receptor 9 (TLR-9) plays an important role in initiating innate immunity. The recognition of self DNA fragments by TLR-9 may results in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].